Search Results 791-800 of 18282 for alopecia

1. Blepharitis - Doctors and departments - Mayo Clinic

   Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens ...

2. Lurbinectedin + Doxorubicin In Leiomyosarcoma - Mayo Clinic

   Participants who have not recovered to ≤ Grade 1 or baseline from adverse events attributed to any prior anti-cancer therapy, with the exceptions of alopecia ...

3. Brightline-4: A study to test how well brigimadlin is tolerated by people with a type of cancer called dedifferentiated liposarcoma - Mayo Clinic

   All toxicities related to previous anticancer therapies have resolved to CTCAE Grade ≤ 1 prior to study treatment administration (except for alopecia and ...

4. A Study of SC‑004 in Subjects With Advanced Solid Tumors - Mayo Clinic

   Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration. Satisfactory laboratory ...

5. Science Saturday: A year of new directions and advancements for regenerative medicine - Mayo Clinic News Network

   Regenerative procedures, such as platelet-rich plasma to rejuvenate aging skin and stimulate hair growth for people with alopecia or baldness, are offered on ...

6. A Study of DCC-2618 vs. Sunitinib in Advanced GIST Patients after Treatment with Imatinib - Mayo Clinic

   Resolution of all toxicities from prior therapy to ≤ Grade 1 (or patient baseline) within 1 week prior to the first dose of study drug (excluding alopecia ...

7. Testing The Addition Of An Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery To The Usual Surgery Alone For Treating Advanced Skin Cancer - Mayo Clinic

   ... alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Physiologic ...

8. Mayo Clinic

   YouTube - MSP International Airport - Mayo Clinic Patient Video Guide - Minnesota · Fuel groundbreaking medical research! · About Mayo Clinic · Medical ...

9. A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1) - Mayo Clinic

   ... alopecia or fatigue [up to Grade 2 allowed]) from AEs resulting from prior immunotherapies. Patients who have autoimmune AEs controlled by replacement ...

10. Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma - Mayo Clinic

    Note: Patients with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study. Note: If patients ...